Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol PRSS3 contributors: mct - updated : 05-07-2017
HGNC name protease, serine, 3 (mesotrypsin)
HGNC id 9486
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
HOMOLOGY
interspecies homolog to C.elegans c07g1.1
Homologene
FAMILY peptidase family S1 or trypsin family
CATEGORY enzyme
SUBCELLULAR LOCALIZATION extracellular
basic FUNCTION
  • protease serine, cationic trypsinogen
  • preferential cleavage arg-xaa and lys-xaa
  • is likely involved in keratinocyte terminal differentiation
  • plays an important role in the progression, metastasis and prognosis of human pancreatic cancer
  • important mediator of prostate cancer progression and metastasis
  • is involved in the desquamation process
  • epidermal PRSS3 and CASP14 work cooperatively in PSAP processing and they thereby contribute likely to permeability barrier formation
  • is an isoform of trypsin that is uniquely resistant to polypeptide trypsin inhibitors and can cleave some inhibitors rapidly
  • is an atypical isoform of trypsin, the upregulation of which has been implicated in promoting tumor progression
    • CELLULAR PROCESS protein, degradation
    PHYSIOLOGICAL PROCESS digestion
    PATHWAY
    metabolism
    signaling
    a component
    INTERACTION
    DNA
    RNA
    small molecule
    protein
  • APP/protease nexin 2 is selectively cleaved by mesotrypsin within the Kunitz protease inhibitor domain
  • extra-pancreatic PRSS3 is produced by esophageal adenocarcinoma (EA) and activates likely F2RL1 in an autocrine manner (F2RL1 activation increases cancer cell proliferation, and promotes cancer cell survival)
  • PRSS3 contributes to the desquamation process by activating KLKs and degrading the intrinsic KLKs' inhibitor SPINK5
  • trypsin family member able to cleave proteins containing the kunitz-type domains
  • TFPI2 is a direct substrate of PRSS3, which hydrolyses TFPI2 (most likely at the Kunitz-type domains) blocking its anti migratory capability
    • cell & other
    REGULATION
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --over  
    in epithelial ovarian cancer (EOC)
    constitutional     --over  
    with serotonin transporter and serotonin content, are increased in small intestine of irritable bowel syndrome
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
  • can be used as a predictor of clinical outcome in patients with ovarian cancer and may therefore represent a new prognostic marker
    • Therapy target
    SystemTypeDisorderPubmed
    cancer  
    abolishing PRSS3 functions might be an exploitable strategy as anticancer, particularly anti-vascular, therapy
    cancerendocrinepancreas
    targeting the PRSS3 signalling pathway may be an effective and feasible approach for treatment of this lethal cancer
    ANIMAL & CELL MODELS